D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...
BOSTON - Compass Therapeutics, Inc. (NASDAQ: CMPX) shares gained 2.7% after the clinical-stage oncology company reported progress across its pipeline and provided a business update for 2024. While the ...
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...
Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...
DNLI reports a narrower-than-expected loss for the fourth quarter of 2024. Denali remains on track to submit a BLA for ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research ...
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback